HANOVER, Md., Sept. 13, 2000 (PRIMEZONE) -- NovaScreen Biosciences Corporation (the "Company" or "NovaScreen") today announced the election of Melvin D. Booth, President and Chief Operating Officer of MedImmune, Inc. (Nasdaq:MEDI) to its Board of Directors. Mr. Booth brings to NovaScreen over 20 year's experience as a pharmaceutical and biotechnology industry leader.
Dr. David Manyak, President of NovaScreen stated, "Mel Booth's extraordinary accomplishments and years of experience in the drug and biotechnology industries, especially in the field of genomics, will make him an extremely valuable contributor to the future growth of our company. I am very pleased that he has joined our Board of Directors."
"NovaScreen is well positioned to successfully contribute to the drug discovery process with its Receptor Selectivity Mapping Database(TM) (RSMDB(TM)) product, which is designed to provide users with a way to correlate the interaction of chemicals and their receptors to biological activities," stated Mr. Booth. "I look forward to helping NovaScreen build its presence as a leader in the emerging pharmacoinformatics industry."
Mr. Booth is President and Chief Operating Officer, and a member of the Board of Directors of MedImmune, Inc., a fully integrated biotechnology company, headquartered in Gaithersburg, MD. MedImmune, a component of the S&P 500, is focused on developing and marketing products that address critical medical needs in areas such as infectious disease, immune regulation and cancer.
Prior to joining MedImmune, Mr. Booth was President, Chief Operating Officer and a member of the Board of Directors of Human Genome Sciences, Inc. (Nasdaq:HGSI). While at HGSI, he was involved in growing the business into a leading genomic research and development company with the goal of building a fully integrated pharmaceutical company. Prior to joining HGSI, he served in various executive capacities at Syntex Corporation, a leading pharmaceutical company that was acquired by the Swiss pharmaceutical company, Roche. Mr. Booth is a graduate of Northwest Missouri State University and holds a Certified Public Accountant certificate.
About the Company:
NovaScreen Biosciences Corporation (www.novascreen.com), a leading biotechnology firm, provides drug discovery, and development services worldwide based on molecular screening technologies. Established in 1986, NovaScreen, recognized for innovation in the field of receptor pharmacology, developed the RSMDB, a broad content database and bioinformatics tool. When employed with NovaScreen's data mining tools, a client can determine patterns of chemical/receptor interactions that are correlated with specific biological and drug activities, and clinical outcomes. RSMDB provides powerful statistical predictability to the drug discovery process, which enhances the efficiency of drug development efforts.
In addition to its core technology in receptor and enzyme assays, NovaScreen provides cellular and molecular biology services to clients in the pharmaceutical, biotechnology and other related industries worldwide. The Company also maintains a library of unique marine compounds and other natural products that it employs to develop pharmaceutical and industrial products.
Currently, NovaScreen counts as its client's two thirds of the world's leading drug companies with over 150 clients worldwide.